Skip to main content

Table 3 LS mean change from Baseline in mSASSS and the different in LS means in MEASURE 1 vs ENRADAS

From: Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison

  MEASURE 1 (N = 201); ENRADAS (N = 122)
n (% of N)
LS mean change (SE) from BL in mSASSS Difference in LS means (SE)
(MEASURE 1 vs. ENRADAS)
p value
Primary analysis set (BL to Days 31–743) M: 168 (84%); E: 69 (57%) M: 0.55 (0.139); E: 0.89 (0.216) −0.34 (0.257); p = 0.1852
Sensitivity analysis set 1 (BL to Days 640–819) M: 178 (89%); E: 82 (67%) M: 0.69 (0.153); E: 0.72 (0.225) −0.03 (0.272); p = 0.9175
Sensitivity analysis set 2, (All patients)a M: 201 (100%); E: 122 (100%) M: 0.68 (0.168); E: 0.99 (0.217) −0.31 (0.280); p = 0.2636
  1. BL Baseline, E ENRADAS, LS Least squares, M MEASURE 1, mSASSS Modified stoke ankylosing spondylitis spinal score, SE Standard error, n Number of patients per cohort in each analysis set, N Total number of patients per cohort
  2. aAll patients with BL (≤ Day 30) and post-BL (> Day 30) radiographs, adjusted for the difference in time between BL and post-BL radiographs